First Read: WebjetLimited "UBS SnapShot: 1H19 Results" (Buy) Plumbe
ONE LINER
A strong result – in-line with UBSe, which on first cut suggests u/lyingorganic EBITDA growth of +16%, or +21% adj for FX loss. Strong performance fromEurope B2B and early Euro summer indications "show a strong rebound".TC the one disappointment.
KEY NUMBERS
Revenue $175m (+33% yoy / -1% vs UBSe $176m). EBITDA $58.0m (+42% yoy /-1% vs UBSe $58.3m. NPATA $38.3m (+61% yoy / +1% vs UBSe $38.1m). Interim DPS8.5cps (UBSe 12.5cps).
RESULT HIGHLIGHTS
1) Webjet rev +12%, EBITDA +11% (vs UBSe +11%), o/performing mkt growthby ~3x;2) Online Republic rev +8%, EBITDA +14% (UBSe +7%);3) B2B rev +72%,EBITDA +136% (UBSe+128%), but organic TTV +21% and EBITDA +24%;4) B2B Europeorganic TTV +22% vs mkt +2% and improving EBITDA margins;5) Corp costs included$1.8m FX loss to unwind hedging book;6) Operating CF of -$26.1m (UBSe -$18.7m),h/line conversion -7%, but normalised conversion (pre I&T) 95% (adj. for$53m ERP payments)
VALUATION
Our $20.20 PT is based on our blended 1yr fwd adjusted PER valuation of$17.39 (50%) and $22.99 DCF valuation (50%).
GUIDANCE
Management reconfirmed FY19E guidance of at least $120m EBITDA ($110munderlying + $10m DOTW). Targeting 3x mkt growth for B2C and 5x for B2B. FY20EThomas Cook TTV $300-450m (UBSe $526m). TC + DOTW + new Asia Pac opportunitiesto deliver > $40m in FY20E (vs UBSe $46m).
UBS COMMENT
A very solid result and outlook commentary (particularly around Europe)should be much stronger than market feared. U/lying growth stronger vs UBSe,but TC expectations disappointing (~$6m below UBSe, but this is only -3% ofFY20E EBITDA).
- Forums
- ASX - By Stock
- WEB
- cracking result
WEB
web travel group limited
Add to My Watchlist
4.01%
!
$4.31

cracking result, page-10
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.31 |
Change
-0.180(4.01%) |
Mkt cap ! $1.560B |
Open | High | Low | Value | Volume |
$4.49 | $4.52 | $4.27 | $12.74M | 2.931M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 3504 | $4.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.32 | 15272 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
37 | 34202 | 4.320 |
15 | 31838 | 4.310 |
24 | 63080 | 4.300 |
17 | 58871 | 4.290 |
18 | 52506 | 4.280 |
Price($) | Vol. | No. |
---|---|---|
4.330 | 31020 | 10 |
4.340 | 14858 | 16 |
4.350 | 33421 | 13 |
4.360 | 38859 | 15 |
4.370 | 23586 | 12 |
Last trade - 12.33pm 27/06/2025 (20 minute delay) ? |
Featured News
WEB (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online